ESMO 2018 | SOLO-1: practice changing data on olaparib for ovarian cancer

Kathleen Moore

Olaparib may be beneficial for patients with advanced, BRCA-mutated ovarian cancer according to the results of the SOLO-1 trial (NCT01844986) presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Here, Kathleen Moore, MD, principle investigator, from the Stephenson Cancer Center, Oklahoma City, OK, delivers the potentially practice-changing results that show maintanance therapy with olaparib reduced the risk of disease progression by 70% compared with placebo. Dr Moore comments on the tolerability of olaparib, with manageable, low-grade toxicities. This study further highlights the necessity of determining BRCA-mutated status at time of diagnosis in order to help guide targeted therapy.

Share this video